You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors.
The company and the Harvard TH Chan School of Public Health will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon.
Under a two-year partnership, the companies plan to discover targets and disease mechanisms for infertility and pregnancy-related conditions, including preeclampsia.
The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.
Harvard Medical School researchers developed a model that attributes the range of meiotic phenotypes to the effects of chromosome compaction.
The PCR-based tests, which detect regions in the virus' nucleocapsid gene, may only be performed at their developers' CLIA-certified labs.
The first year's pilot phase aimed to develop an infectious disease digital health and precision medicine platform connecting healthcare facilities to NYSDOH.
he firm will use the proceeds to expand manufacturing capacity for its existing and in-development COVID-19 assays.
The company said it will use the two-year grant to optimize its LC manufacturing process and development new chromatography products.
The technologies, called non-extensible oligonucleotides and linear DNA assembly, may help the sample prep firm improve existing products.
Most of the scroll fragments analyzed originated from sheep, but two pieces came from cow, suggesting they were imported to the area where they were found.
The workflow combines Swift's Adaptase technology and RNA library kits with Arbor's myBaits technology for hybridization-based target enrichment of the virus.
The company said it is using the technology for synthetic biology, diagnosis of inherited genetic diseases, liquid biopsy, and infectious disease detection.
The companies are applying Personalis' technology to explore immune response to genetic therapeutics in Sarepta's pipeline.
Alphazyme will manufacture three Codexis enzymes, including a new high-fidelity DNA polymerase, and gain comarketing rights to certain other Codexis enzymes.
Seven Bridges will help build a computational infrastructure to harmonize data from Zero Childhood Cancer with datasets from other research projects.
The company, along with Softbank Investment Advisers, is offering a total of 11.5 million shares of its common stock at $84 per share.
In its complaint, the Maryland-based company claimed that Natera infringes two of its patents, both titled "Methods for detection of genetic disorders."
The company plans to use the funds for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility.
The company already offers an antibody test, Anti-SARS-CoV-2 Rapid Test, that it is distributing for its Chinese joint venture partner Autobio Diagnostics.
The firms will offer SARS-CoV-2 testing using a rapid, on-site device as well as lab-based test services.
The GenomeWeb Index rose more than 9 percent in May, following an 18 percent climb in April, a marked contrast to its negative performance in February and March.
Genomic data should be easily accessible to patients and their physicians through electronic health record systems with privacy safeguards.
Three teams have developed base editors that combine the abilities of adenine and cytosine base editors, allowing for concurrent A-to-G and C-to-T edits.
Ancestry patterns appeared to shift in parts of northern China during the Neolithic and Bronze Age as populations transitioned to farming-focused and pastoralist subsistence strategies.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.